Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial-Reference-Cited by-同舟云学术

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

Published:2024-04 Issue:4 Volume:23 Page:382-392
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Tassorelli Cristina,Nagy Krisztián,Pozo-Rosich Patricia,Lanteri-Minet Michel,Sacco Sara,Nežádal Tomáš,Guo Hua,De Abreu Ferreira Rosa,Forero Giovanna,Trugman Joel M

Funder

AbbVie

Publisher

Elsevier BV

Reference29 articles.

1. The international classification of headache disorders. 3rd edition;Cephalalgia,2018

2. Migraine: epidemiology, burden, and comorbidity;Burch;Neurol Clin,2019

3. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019;Steiner;J Headache Pain,2020

4. International classification of headache disorders—ICHD-4 alpha;Goadsby;Cephalalgia,2020

5. A Comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American migraine prevalence and prevention (AMPP) study: demographics and headache-related disability;Lipton;Headache,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine;Headache: The Journal of Head and Face Pain;2024-09-09

2. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine;Cephalalgia;2024-09

3. Causality between migraine and cardiovascular disease: a bidirectional Mendelian randomization study;The Journal of Headache and Pain;2024-08-13

4. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases;Frontiers in Pharmacology;2024-07-31

5. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial;Neurology;2024-07-23